Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
HIK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,690.00p - 2,360.00p
Previous CloseN/A
Volume7.28K
Average Volume (3M)556.79K
Market Cap
£4.01B
Enterprise Value5.40B
Total Cash (Recent Filing)£213.00M
Total Debt (Recent Filing)£1.31B
Price to Earnings (P/E)14.2
Beta0.76
Next Earnings
Feb 19, 2026EPS EstimateN/A
Last Dividend Ex-Date
Aug 14, 2025Dividend Yield3.49%
Share Statistics
EPS (TTM)0.91
Shares Outstanding221,886,460
10 Day Avg. Volume556,310
30 Day Avg. Volume556,794
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,471.50Price Target Upside35.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHikma delivered a top of range FY24 print and successfully navigated a tough comp year, delivering approximately 6% beat to core EBIT vs guidance at the start of 2024.
Growth StrategyCMO strategy could gain momentum, which is considered value-accretive, with a 'significant' long-term partnership expected to commercialize products in 2027.
Market PositionStrong demand in European and MENA markets, while North America benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio.
Bears Say
Guidance And ForecastsWe update our forecasts, with a 2% reduction to FY25 core EBIT and 5% reduction to adj. EPS also reflecting higher interest charges.
Market ReactionA market overreaction has created an opportunity for investors, as recent macro tariff news has inappropriately affected Hikma, exposing both short- and long-term opportunity.
Profit MarginsCompany continues to expect 7-9% FY25 revenue growth, with phasing and mix of sales expected to impact margins in 1H, but FY25 core operating margin maintained in the mid-30s.
Hikma Pharmaceuticals News
HIK FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest share price was 1690.00p and its highest was 2360.00p in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Hikma Pharmaceuticals PLC’s market cap is £4.01B.
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Feb 19, 2026 which is in 175 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Aug 07, 2025. The company reported 0.908p earnings per share for the quarter, the consensus estimate of 0.908p by 0p.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC pays a Semiannually dividend of 26.556p which represents an annual dividend yield of 3.49%. See more information on Hikma Pharmaceuticals PLC dividends here
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of 0.908p in its last earnings report, expectations of 0.908p. Following the earnings report the stock price went down -7.112%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in GB:HIK
Hikma Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£2,471.50 (35.80% Upside)
£2,471.50 (35.80% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth £930.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.62%
12-Months-Change
Fundamentals
Return on Equity
15.66%
Trailing 12-Months
Asset Growth
5.70%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC is a global pharmaceutical company headquartered in London, UK, that specializes in the development, manufacturing, and marketing of a broad range of generic and branded medications. The company operates primarily through two main business segments: Injectables and Generics, as well as a growing portfolio of branded products. Hikma’s core offerings include injectable medications, oral solids, and specialty pharmaceuticals, with a focus on therapeutic areas such as oncology, cardiovascular, and pain management.
HIK Stock 12 Month Forecast
Average Price Target
2,471.50p
▲(35.80% Upside)
Technical Analysis
Allergy Therapeutics
―
―
Animalcare
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―
Ownership Overview
7.87% Insiders
4.96%
Mutual Funds
― Other Institutional Investors
77.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---